Researchers have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer (PCa), according to study findings published online in The Lancet ...
About 25%-33% of men with prostate cancer (PCa) will experience a recurrence of their cancer after primary radiation therapy. Among the various salvage treatments available is salvage radical ...
A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. Background: To date, docetaxel (D) is the only chemotherapy agent that has provided a survival ...
The phase 2 ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial tested a cooled laser focal therapy device for intermediate-risk prostate cancer treatment.
Bayer HealthCare provided support for this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results